When practices, promises, profits, and policies outpace hard evidence: The post-menopausal hormone debate

Journal of Social Issues

Volumn 61, Issue 1, 2005, Pages 159-179

  Naughton, Michelle J ^a   Jones, Alison Snow ^a   Shumaker, Sally A ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b Natl Women's Hlth Ctr Excellence   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN;

WOMENS HEALTH;

AGE; ARTICLE; CLINICAL TRIAL; CLINICAL TRIAL (TOPIC); DRUG EFFECT; DRUG INDUSTRY; DRUG LABELING; ESTROGEN THERAPY; FEMALE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE AND PUBLIC HEALTH; HEALTH CARE ORGANIZATION; HEALTH PERSONNEL ATTITUDE; HUMAN; MENOPAUSE; MIDDLE AGED; NATIONAL HEALTH ORGANIZATION; PHYSICIAN; POSTMENOPAUSE; QUALITY OF LIFE; RISK ASSESSMENT; UNITED STATES; WOMEN'S HEALTH; WOMEN'S HEALTH INITIATIVE;

HEALTH CARE AND PUBLIC HEALTH; WOMEN'S HEALTH INITIATIVE;

AGE FACTORS; ATTITUDE OF HEALTH PERSONNEL; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; DRUG INDUSTRY; DRUG LABELING; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; NATIONAL INSTITUTES OF HEALTH (U.S.); PHYSICIANS; POSTMENOPAUSE; PROGESTINS; QUALITY OF LIFE; RISK ASSESSMENT; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; WOMEN'S HEALTH;

EID: 15844427067     PISSN: 00224537     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0022-4537.2005.00399.x     Document Type: Article

References (84)

1. Achilles, C., & Leppert P. C. (1997). The menopausal woman. In P. C. Leppert & F. M. Howard (Eds.), Primary care for women (pp. 97-102). Philadelphia: Lippincott-Raven Publishers.
2. Amundsen, D. W., & Diers, C. J. (1973). Age of menopause in medieval Europe. Human Biology, 25, 605.
3. Associated Press. (2004, January 6). Hormone prescriptions drop after risks found in study. The Wall Street Journal. Retreived January 29, 2004, from http://www.WSJ.com
4. Avis, N. E., Crawford, S., Stellato, R., & Longcope, C. (2001). Longitudinal study of hormone levels and depression among women transitioning through menopause. Climacteric, 4, 243-249.
5. Bailar, J. (2003). Hormone-Replacement theraphy and cardiovascular diseases. The New England Journal of Medicine, 349(6), 521-522.
6. Barbaro, M. (2002, September 17). Novavax faces tough sales job on drug: Hormone-replacement concerns could sink Estrasorb even if FDA doesn't. The Washington Post (fina ed.). Retrieved April 24, 2004, from Lexis-Nexis database.
7. Barnabei, V. M., Grady, D., Stovall, D. W., Cauley, J. A., Lin, F., Stuenkel, C. A., et al. (2002). Menopausal symptoms in older women and the effects of treatment with hormone therapy. Obstetrics and Gynecology, 100, 1209-1218.
8. Barrett, A. (2002, July 25). Good news about HRT-for inventors. Business Week. Retrieved October 13, 2003, from http:// www.businessweek.com/technology/content/jul2002/tc20020725_9019.htm
9. Benedek, T. (1950). Climacterium: A developmental phase. Psychoanalysis Quarterly, 19, 1-27.
10. Birge, S. M. (1997). The role of estrogen in the treatment and prevention of dementia: Introduction. American Journal of Medicine, 103(suppl.), 1S-2S.
11. Buxton, C. L., & Engle, E. T. (1939). Effects of the therapeutic use of diethylstilboestrol. Journal of the American Medical Association, 113 2318-2320.
12. Davidoff, F., DeAngelis, C. D., Drazen, J. M., Hoey, J., Hojgaard, L., Horton, R., et al. (2001). Sponsorship, authorship and accountability. Lancet, 358, 854-856.
13. Deutsch, H. (1945). Psychology of women: A psychoanalytic interpretation. In (Ed.), Motherhood: Vol. 11 (pp. 456-491). New York: Grune and Stratton.
14. Espeland, M. A., Rapp, S. R., Shumaker, S. A., Brunner, R., Manson, J. E., Sherwin, B. B., et al. (2004). Conjugated equine estrogens and global cognitive function in postmenopausal women. JAMA, 291, 2959-2968.
15. Estrogen and progestin use in peri- and post-menopausal women. (2003, September). Position Statement of the North American Menopause Society. Menopause, 10(6), 497-506.
16. Fixing the drugs pipeline. (2004). The Economist (March 13th-19th), 37-38.
17. Fletcher, S. W., & Colditz, G. A. (2002). Failure of estrogen plus progestin therapy for prevention. Journal of the American Medical Association, 288(3), 366-368.
18. Friedman, L. M., Furberg, C. D., DeMets, D. L. (1996).Fundamentals of clinical trials (third ed.). St. Louis, MO: Mosby Press.
19. Gannon, L. (1990). Endocrinology of menopause. In R. Formanek (Ed.), The meanings of menopause: Historical, medical and clinical perspectives (pp. 179-237). Hillsdale, NJ: Analytic Press.
20. Grady, D. (2003). Postmenopausal hormones-Theraphy for symptoms only. The New England Journal of Medicine, 348(19), 1835-1837.
21. Grady, D., Rubine, S. M., Petitti, D. B., Fox, C.S., Black, D., Ettinger, B., et al. (1992). Hormone therapy to prevent disease and prolong life in postmenopausal women. Annals of Internal Medicine, 117, 1016-1037.
22. Grady, D., Wenger, N. K., Herrington, D., Khan, S., Furberg, C., Hunninghake, D., et al. (2000). Postmenopausal hormone therapy increases risk for venous thromboembolic disease: The heart estrogen/progestin replacement study. Annals of Internal Medicine, 132(9), 689-696.
23. Greendale, G., Reboussin, B., Hogan, P., Barnabei, V. M., Shumaker, S., Johnson, S., et al. (1998). Symptom relief and side effects of postmenopausal hormones: Results from the postmenopausal estrogen/ progestin interventions trial. Obstetrics and Gynecology, 92, 982-988.
24. Grodstein, F., Clarkson, T. B,, & Manson, J. E. (2003). Understanding the divergent data on postmenopausal hormone therapy. The New England Journal of Medicine, 348(7), 645-650.
25. Grodstein, E, & Stampfer, M. (1995). The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Progress in Cardiovascular Diseases, 38(3), 199-210.
26. Herper, M. (2002, September 4). Wyeth cautious on long-term hormone use. Forbes. Retrieved October 13, 2003, from http://www.forbes.com/ 2002/09/04/0904wye.html
27. Hays, J., Ockene, J. K., Brunner, R. L., Kotchen, J. M., Manson, J. E., Patterson, R. E., et al. (2003). Effects of estrogen plus progestin on health-related quality of life. The New England Journal of Medicine, 348(19), 1839-1854.
28. Healy, B. (1995). Menopause: The new prime time. In A new prescription for women's health (pp. 173-213). New York: Viking Penguin.
29. Henderson, V. W., Paganini-Hill, A., Miller, B. L., Elble, R. J., Reyes, P. F., Shoupe, D., et al. (2000). Estrogen for Alzheimer Disease in women: Randomized, double-blind, placebo-controlled trial. Neurology, 54, 295-301.
30. Hensley, S. (2002, July 10). Wyeth stock slides as study casts shadow on medicines. The Wall Street Journal. Retrieved October 23, 2003, from http://www.WSJ.com
31. Hensley, S., & Landers, P. (2003). Drug companies report pain. The Wall Street Journal Online, October 23, 2003. Retrieved October 23, 2003 from, www.WSJ.com.
32. Herrington, D. M., & Howard, T. D. (2003). From presumed benefit to potential harm-Hormone therapy and heart disease. The New England Journal of Medicine, 349(6),519-521.
33. Herrington, D. M., Reboussin, D. M., Broshnihan, K. B., Sharp, P. C., Shumaker, S. A., Snyder, T. E., et al. (2000). Effects of estrogen replacement on the progression of coronary artery atherosclerosis. The New England Journal of Medicine, 343, 522-529.
34. Hersh, L., Stefanick, M. L., & Stafford, R. S. (2004). National use of postmenopausal hormone therapy. Annual trends and response to recent evidence. Journal of the American Medical Association, 291, 47-53.
35. Hilts, P. J. (2003). Protecting America's health: The FDA, business, and one hundred years of regulation. New York: Alfred J. Knopf.
36. Hodis, H. N., Mack, W. J., Azen, S. P., Lobo, R. A., Shoupe, D., Mahrer, P. R., et al. (2003). Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. The New England Journal of Medicine, 349, 535-545.
37. Hovey, H. H. (2004, April 22). Wyeth's profit declines by 41% skewed by big year-earlier gain. The Wall Street Journal. Retrieved April 22, 2004, from http://www.WSJ.com
38. Hulley, S., Grady, D., Bush, T., Furberg, C., Herrington, D., Riggs, B., et al. (1998). Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post-menopausal women. Journal of the American Medical Association, 280, 605-613.
39. Hunt, M. (2002, May). Changing patterns of pharmaceutical innovation Washington, DC: National Institute for Health Care Management.
40. Ignelzi, R. J. (2003, November 24). Women weigh the risks vs. the benefits of hormone therapy. Copley News Service. Retrieved April 24, 2004, from Lexis-Nexis database.
41. Keating, N. L., Cleary, P. D., Rossi, A. S., Zaslavsky, A. M., & Ayanian, J. Z. (1999). Use of hormone replacement therapy by postmenopausal women in the United States. Annals of Internal Medicine, 130, 545-553.
42. Kolata, G. (2002, November 10). Menopause without pills: Rethinking hot flashes. The New York Times (Sunday, late ed.-final). Retrieved April 22, 2004, from Lexis-Nexis database.
43. Kreling, D., Mott, D., Widerholt, J., Lundy, J., & Levitt, L. (2001). Prescription drug trends: A chartbook update. Menlo Park, CA: Kaiser Family Foundation.
44. Landers, P. (2004, February 24). Drug industry's big push into technology falls short. The Wall Street Journal. Retrieved February 24, 2004, from http://www.WSJ.com
45. Letters to the Editor. (2002). Journal of the American Association, 288(22), 2819-2825.
46. MacBryde, C. M., Freedman, H., & Loeffel, E. (1939). Studies on stilbestrol: Preliminary statement. Journal of the American Medical Association, 113, 2320.
47. MacLennan, A., Lester, S., & Moore, V. (2001). Oral estrogen replacement therapy versus placebo for hot flushes: A systematic review. Climacteric, 4, 58-74.
48. Manson, J. E., Hsia, J., Johnson, K. C., Rossouw, J. E. Assaf, A. R., Lasser, N. L., et al. (2003). Estrogen plus progestin and the risk of coronary heart disease. The New England Journal of Medicine, 349 6), 523-534.
49. Market Information (WYE). (2003). New York Stock Exchange. Retrieved October 27, 2003, from http://www.nyse.com/marketinfo
50. Market Information (WYE). (2004). New York Stock Exchange. Retrieved March 23, 2004, from http://www.nyse.com/marketinfo
51. Mathews, A., & Hensley, S. (2003, October 8). Hormone-Therapy debate grows. The Wall Street Journal. Retrieved October 13, 2003, from http://www.wsj.com
52. McKinlay, S., Brambilla, D., & Posner, J. (1992). The normal menopause transition. Maturitas, 14, 103-115.
53. Moynihan, R. (2003). The making of a disease: Female sexual dysfunction. British Medical Journal, 326, 45-47.
54. Moynihan, R., Heath, I. & Henry, D. (2002). Selling sickness: The pharmaceutical industry and disease mongering. British Medical Journal, 324, 886-889.
55. National Center for Health Statistics. (1999). Health United States, 1999 with the health and aging chartbook (PHS 99-1232). Hyattsville, MD: U.S. Department of Health and Human Services.
56. Nelson, H. D., Humphrey, L. L., Nygren, P., Teutsch, S. M., & Allan, J. D. (2002). Postmenopausal hormone replacement: Scientific review. Journal of the American Medical Association, 288, 872-881.
57. Premarin full revised label. (2003, January). Retrieved December 2, 2004, from: http://www.fda.gov/medwatch/SAFETY/2003/premarin-PI.pdf
58. Prempro/Premphase/full revised label. (2003, January). Retrieved June 23, 2004, from: http://www.fda.gov/medwatch/SAFETY/2003/ prempro_PI.pdf
59. Rapp, S. R., Espeland, M. A., Shumaker, S. A., Henderson, V. W., Brunner, R. L., Manson, J. E., et al. (2003). Effect of estrogen plus progestin on global cognitive function in postmenopausal women: The Women's Health Initiative Memory Study: A randomized controlled trial. Journal of the American Medical Association, 289(20), 2663-2672.
60. Resnick, S. M., Maki, P. M., Golski, S., Kraut, M. A., & Zonderman, A. B. (1998). Effects of estrogen replacement therapy on PET cerebral blood flow and neuropsychological performance. Hormones and Behavior, 34 171-182.
61. Reuben, D. (1969). Everything you always wanted to know about sex. New York: Harper Collins.
62. Robinson, R. W., Cohen, W. D., & Higano, N. (1958). Estrogen replacement therapy in women with coronary atherosclerosis. Annals of Internal Medicine, 48, 95-101.
63. Schmidt, P. J., & Rubinow, D. (1991). Menopause-Related affective disorders: A justification for further study. American Journal of Psychiatry, 148, 844-852.
64. Seaman, B. (2003). The greatest experiment ever performed on women New York: Hyperion Books.
65. Schering defends hormone drugs in the wake of halt of U.S. study, (2002, July 10). The Wall Street Journal. Retrieved October 13, 2003, from http://www.wsj.com
66. Shorr, E., Robinson, F. H., & Papanicolaou, G. N. (1939). A clinical study of the synthetic estrogen, stilbestrol. Journal of the American Medical Association, 113, 2312-1318.
67. Shumaker, S. A., Legaut, C., Rapp, S. R., Thal, L., Wallace, R. B., Ockene, J. K., et al. (2003). Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The women's health initiative memory study: A randomized controlled trial. Journal of the American Medical Association, 289(20), 2651-2662.
68. Shumaker, S. A., Legault, C., Kuller, L., Rapp, S. R., Thal, L., Lane, D. S., et al. (2004). Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in post-menopausal women. JAMA, 291, 2947-2958.
69. Shumaker, S. A., Reboussin, B. A., Espeland, M. A., Rapp, S. R., Mcbee, W. L., Dailey, M., et al. (1998). The Women's Health Initiative Memory Study (WHIMS): A trial of the effect of estrogen therapy in preventing and slowing the progression of dementia. Controlled Clinical Trials, 19, 604-621.
70. Smith, S. (2003, July 20). Hormone therapy's rise and fall: Science lost its way and women lost out. The Boston Globe (Sunday, 3rd ed.), p. A1.
71. Spake, A. (2002, November 18). The menopausal marketplace. U.S. News & World Report, pp. 1-6. Retrieved July 2, 2004, from http:// USNews.com
72. Stampfer, M. J., & Colditz, G. A. (1991). Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence. Preventive Medicine, 20, 47-63.
73. Starr, P. (1982). The social transformation of American medicine. New York: Basic Books.
74. Swartzman, L. D., & Leiblum, S. R. (1987). Changing perspectives on the menopause. Journal of Psychosomatic Obstetrics and Gynecology, 6, 11-24.
75. U.S. Census Projections. (2003). Retrieved, from U.S. Census Web site: http://www.census.gov/population/projections/nation/summary/ np-13-b.pdf
76. Utian, W. H. (1980). Menopause in modern perspective: A guide to clinical practice. New York: Appleton-Century-Crofts.
77. Wassertheil-Smoller, S., Hendrix, S. L., Limacher, M., Heiss, G., Kooperberg, C., Baird, A., et al. (2003). Effect of estrogen plus progestin on stroke in postmenopausal women. Journal of the American Medical Association, 289, 2673-2684.
78. Waters, D. D., Alderman, E. L., Hsia, J., Howard, B. V., Cobb, F. R., Rogers, W. J., et al. (2002). Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: A randomized controlled trial. Journal of the American Medical Association, 288, 2432-2440.
79. Wilson, R. A. (1966). Feminine forever. New York: M. Evans and Company, Inc.
80. The Women's Health Initiative Steering Committee. (2004). Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. Journal of the American Medical Association, 291, 1701-1712.
81. The Women's Health Initiative Study Group. (1998). Design of the Women's Health Initiative Clinical Trial and Observational Study. Controlled Clinical Trials, 19, 61-109.
82. Writing Group for the PEPI Trial. (1995). Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. Journal of the American Medical Association, 273(3), 199-208.
83. Writing Group for the Women's Health Initiative Investigators. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Journal of the American Medical Association, 288(3), 321-333.
84. Yaffe, K., Sawaya, G., Lieberburg, I., & Grady, D. (1998). Estrogen therapy in postmenopausal women: Effects on cognitive function and dementia. Journal of the American Medical Association, 285, 1489-1499.